
1. Malar J. 2016 Feb 18;15:96. doi: 10.1186/s12936-016-1141-9.

Plasmodium vivax mdr1 genotypes in isolates from successfully cured patients
living in endemic and non-endemic Brazilian areas.

Gomes LR(1)(2), Almeida-de-Oliveira NK(3)(4), de Lavigne AR(5)(6), de Lima
SR(7)(8), de Pina-Costa A(9)(10), Brasil P(11)(12), Daniel-Ribeiro CT(13)(14),
Ménard D(15), Ferreira-da-Cruz Mde F(16)(17).

Author information: 
(1)Laboratório de Pesquisa em Malária - Instituto Oswaldo Cruz, Fundação Oswaldo 
Cruz (Fiocruz), Rio de Janeiro, Brazil. larissagomesr@gmail.com.
(2)Centro de Pesquisa, Diagnóstico e Treinamento em Malária (CPD-Mal) Fiocruz,
Rio de Janeiro, Brazil. larissagomesr@gmail.com.
(3)Laboratório de Pesquisa em Malária - Instituto Oswaldo Cruz, Fundação Oswaldo 
Cruz (Fiocruz), Rio de Janeiro, Brazil. nataliaketrin@gmail.com.
(4)Centro de Pesquisa, Diagnóstico e Treinamento em Malária (CPD-Mal) Fiocruz,
Rio de Janeiro, Brazil. nataliaketrin@gmail.com.
(5)Laboratório de Pesquisa em Malária - Instituto Oswaldo Cruz, Fundação Oswaldo 
Cruz (Fiocruz), Rio de Janeiro, Brazil. alinelavigne@uol.com.br.
(6)Centro de Pesquisa, Diagnóstico e Treinamento em Malária (CPD-Mal) Fiocruz,
Rio de Janeiro, Brazil. alinelavigne@uol.com.br.
(7)Laboratório de Pesquisa em Malária - Instituto Oswaldo Cruz, Fundação Oswaldo 
Cruz (Fiocruz), Rio de Janeiro, Brazil. suelen.lima@ioc.fiocruz.br.
(8)Centro de Pesquisa, Diagnóstico e Treinamento em Malária (CPD-Mal) Fiocruz,
Rio de Janeiro, Brazil. suelen.lima@ioc.fiocruz.br.
(9)Centro de Pesquisa, Diagnóstico e Treinamento em Malária (CPD-Mal) Fiocruz,
Rio de Janeiro, Brazil. anielle.pina@hotmail.com.
(10)Laboratório de Doenças Febris Agudas - Instituto Nacional de Infectologia
Evandro Chagas (INI-IPEC) (Fiocruz), Rio de Janeiro, Brazil.
anielle.pina@hotmail.com.
(11)Centro de Pesquisa, Diagnóstico e Treinamento em Malária (CPD-Mal) Fiocruz,
Rio de Janeiro, Brazil. patricia.brasil@ini.fiocruz.br.
(12)Laboratório de Doenças Febris Agudas - Instituto Nacional de Infectologia
Evandro Chagas (INI-IPEC) (Fiocruz), Rio de Janeiro, Brazil.
patricia.brasil@ini.fiocruz.br.
(13)Laboratório de Pesquisa em Malária - Instituto Oswaldo Cruz, Fundação Oswaldo
Cruz (Fiocruz), Rio de Janeiro, Brazil. ctdr@uol.com.br.
(14)Centro de Pesquisa, Diagnóstico e Treinamento em Malária (CPD-Mal) Fiocruz,
Rio de Janeiro, Brazil. ctdr@uol.com.br.
(15)Malaria Molecular Epidemiology Unit, Institut Pasteur in Cambodia, Phnom
Penh, Cambodia. dmenard@pasteur-kh.org.
(16)Laboratório de Pesquisa em Malária - Instituto Oswaldo Cruz, Fundação Oswaldo
Cruz (Fiocruz), Rio de Janeiro, Brazil. mffcruz28@gmail.com.
(17)Centro de Pesquisa, Diagnóstico e Treinamento em Malária (CPD-Mal) Fiocruz,
Rio de Janeiro, Brazil. mffcruz28@gmail.com.

BACKGROUND: Plasmodium vivax is the most widely distributed species causing the
highest number of malaria cases in the world. In Brazil, P. vivax is responsible 
for approximately 84 % of reported cases. In the absence of a vaccine, control
strategies are based on the management of cases through rapid diagnosis and
adequate treatment, in addition to vector control measures. The approaches used
to investigate P. vivax resistance to chloroquine (CQ) were exclusively in vivo
studies because of the difficulty in keeping parasites in continuous in vitro
culture. In view of the limitations related to follow-up of patients and to
assessing the plasma dosage of CQ and its metabolites, an alternative approach to
monitor chemo-resistance (QR) is to use molecular markers. Single nucleotide
polymorphisms (SNPs) in the multidrug resistance gene pvmdr1 are putative
determinants of CQ resistance (CQR), but such SNPs in P. vivax isolates from
patients with good response to treatment should be further explored. The aim of
this study is to investigate the mutations in the gene, supposedly associated to 
QR, in P. vivax isolates from successfully cured patients, living in Brazilian
endemic and non-endemic areas.
METHODS: Blood samples were collected from 49 vivax malaria patients from endemic
(Amazon Basin: 45) and non-endemic (Atlantic Forest: four) Brazilian regions and 
analysed for SNPs in the CQR-related P. vivax gene (pvmdr1), using PCR-based
methods.
RESULTS: Among the 49 isolates genetically characterized for the gene pvmdr1, 34 
(70 %) presented at least one mutation. T958M mutant alleles were the most
frequent (73 %) followed Y976F (15 %) and F1076L (12 %). Single mutation was
detected in 24 (70.5 %) isolates and double mutations in ten (29.5 %). The most
common single mutant genotype was the 958M/Y976/F1076 (79 %), followed by
976F/F1076 (21 %) whereas 958M/Y976/1076L (60 %) and 976F/1076L (40 %) double
mutant genotypes were detected. Single mutant profile was observed only in
isolates from Amazon Basin, although double mutants were found both in the Amazon
and Atlantic Forest regions. Interestingly, the genotype 958M/Y976/1076L was
present in all isolates from the Atlantic Forest in the Rio de Janeiro State.
CONCLUSIONS: Considering that primaquine (PQ) efficacy is highly dependent on
concurrent administration of a blood schizontocidal agent and that PQ could not
circumvent CQR, together with the fact that no pvmdr1 mutation should be expected
in successfully cured patients, these findings seem to indicate that the pvmdr1
gene is not a reliable marker of CQR. Further investigations are needed to define
a reliable molecular marker for monitoring P. vivax CQR in P. vivax populations.

DOI: 10.1186/s12936-016-1141-9 
PMCID: PMC4758108
PMID: 26887935  [Indexed for MEDLINE]

